C4orf17

Across TCGA pan-cancer cohorts, C4orf17 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of C4orf17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where C4orf17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types C4orf17 is over-expressed in tumor, although a few such as BLCA and STAD show the opposite, repressed pattern.

KIRP, THCA, and LUSC are the cancer types where C4orf17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C4orf17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	III,IV	+0.031	.001	8	view →
THCA	All	All	+0.036	<.001	5	view →
LUSC	Male	All	+0.104	.001	4	view →
HNSC	Male	All	+0.037	.026	4	view →
BLCA	All	IV	−0.022	.005	2	view →
STAD	Male	II,III,IV	−0.019	.042	1	view →
KIRC	Male	All	+0.009	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

C4orf17–KIRP

Open the KIRP breakdown →